Alopecia Areata with Good Response to Tofacitinib

October 2020 in “ Der Hautarzt ”

A. Maksimow, David Stintzing, Johannes Wohlrab

alopecia areata alopecia areata universalis tofacitinib glucocorticoids PUVA therapy dithranol Xeljanz corticosteroids psoralen and ultraviolet A therapy

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Studysummary This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document presented a case study of a 46-year-old woman with active inflammatory alopecia areata universalis who experienced full regrowth of scalp hair after being treated with 2 × 5 mg per day of tofacitinib for 18 months. Previous treatments with topical and systemic glucocorticoids, cream PUVA therapy, and dithranol were unsuccessful. Hair growth began after 4-6 months of tofacitinib treatment, which was well tolerated. This case demonstrated that the off-label use of tofacitinib could be a potential therapeutic option for alopecia areata.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

54 citations , September 2019 in “Journal of the European Academy of Dermatology and Venereology”

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

research The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review

19 citations , August 2019 in “Dermatologic therapy”

This review discusses the use of Janus kinase inhibitors for alopecia areata and reports promising short-term efficacy but low-quality evidence, highlighting the need for further research to confirm long-term safety and effectiveness.

research Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata

55 citations , October 2015 in “Journal of Investigative Dermatology”

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

research The Genetics Of Alopecia Areata: New Approaches, New Findings, New Treatments

62 citations , January 2015 in “Journal of Dermatological Science”

This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , June 2014 in “Journal of Investigative Dermatology”

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

research The Role of Hair Follicle Immune Privilege Collapse in Alopecia Areata: Status and Perspectives

79 citations , December 2013 in “Journal of Investigative Dermatology Symposium Proceedings”

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.